Drugs / CN-105
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02670824 | Dec 2015 → May 2016 | intracerebral hemorrhage | AegisCN LLC | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06255977 | Aug 2022 → May 2024 | intracerebral hemorrhage | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03711903 | Mar 2019 → Jun 2022 | intracerebral hemorrhage | National Neuroscience Institute | Completed | No outcome recorded |
| Phase 2 | NCT03802396 | Jul 2018 → Dec 2022 | delirium, subjective cognitive decline | Miles Berger, MD PhD | Completed | No outcome recorded |
| Phase 2 | NCT03168581 | Aug 2017 → Sep 2019 | intracerebral hemorrhage | AegisCN LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CN-105 | “a small 5 amino acid apoE mimetic peptide(CN-105) that mimics the polar face of the apoE helical domain involved in receptor interactions.” PMID 28429734 ↗ Apr 2017 |
| Known as | Ac-val-ser-arg-arg-arg-nh2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314912 ↗ |
| Action | Inhibit | “It is hoped that CN-105 will block signaling via a gene known as ApoE4, the most common gene implicated in late life Alzheimer's disease.” NCT03802396 ↗ |
| Modality | Peptide | “CN-105 is an IV, apolipoprotein E-mimetic pentapeptide.” PMID 35562205 ↗ May 2022 |
| Route | Intravenous | “Single and multiple intravenous (IV) doses of CN-105” NCT02670824 ↗ |
| Target | APOE | “It is hoped that CN-105 will block signaling via a gene known as ApoE4, the most common gene implicated in late life Alzheimer's disease.” NCT03802396 ↗ |